{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:51:28Z","timestamp":1787007088942,"version":"build-2736575974"},"reference-count":80,"publisher":"Informa UK Limited","issue":"4","funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073686"],"award-info":[{"award-number":["82073686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81730108"],"award-info":[{"award-number":["81730108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["and 81973635"],"award-info":[{"award-number":["and 81973635"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Foundation for Scholars of Hangzhou Normal University","award":["2019QDL003"],"award-info":[{"award-number":["2019QDL003"]}]},{"name":"The Ministry of Science and Technology of China (High-end foreign experts program","award":["G20200217005 and G2021017004"],"award-info":[{"award-number":["G20200217005 and G2021017004"]}]},{"name":"Hangzhou\u2019s \u2018115\u2019 plan to introduce overseas intelligence projects","award":["20200215 and 20210120"],"award-info":[{"award-number":["20200215 and 20210120"]}]},{"name":"Hangzhou Normal University, School of Medicine Teaching Reform Fund","award":["4125b30100112"],"award-info":[{"award-number":["4125b30100112"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,4,3]]},"DOI":"10.1080\/13543776.2022.2027911","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T05:14:42Z","timestamp":1641791682000},"page":"401-421","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3991-645X","authenticated-orcid":false,"given":"Suwen","family":"Hu","sequence":"first","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Department of Medicinal Chemistry, Hangzhou Huadong Medicine Group Pharmaceutical Research Institute Co. Ltd. ., Hanzhou City, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-8025","authenticated-orcid":false,"given":"Zi","family":"Hui","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Duan","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-1493","authenticated-orcid":false,"given":"Carmen","family":"Garrido","sequence":"additional","affiliation":[{"name":"Inserm Unit U1231, Label LIPSTIC, University of Bourgogne Franche-comt\u00e9, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-1443","authenticated-orcid":false,"given":"Tian","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-0930","authenticated-orcid":false,"given":"Xiang-Yang","family":"Ye","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,13]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/nature08467"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.2"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0046-z"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00358-6"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.281"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.7.2850"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.2.152"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.24.7002"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0034-3"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100017"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1328-y"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0194-3"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1866540"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2014.10"},{"key":"cit0015","unstructured":"Vertex Pharma. Compounds useful as inhibitors of ATR kinase. WO 2014089379; 2014."},{"key":"cit0016","author":"Vertex Pharma.","year":"2014","journal-title":"WO 2014143242"},{"key":"cit0017","unstructured":"Vertex Pharma. Fused pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase. WO 2014143240; 2014."},{"key":"cit0018","unstructured":"Vertex Pharma. Compounds useful as inhibitors of ATR kinase. US 20150158868; 2015."},{"key":"cit0019","unstructured":"Vertex Pharma. Radiolabelled derivatives of a 2-amino-6-fluoro-N-[5-fluoro-pyridin-3-yl]-pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof. WO 2015187451; 2015."},{"key":"cit0020","unstructured":"Vertex Pharma. 2-amino-6-fluoro-N-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof. WO 2015085132; 2015."},{"key":"cit0021","author":"Vertex Pharma.","year":"2014","journal-title":"US 20140107093"},{"key":"cit0022","unstructured":"Univ Texas. Tetrahydropyrido[4,3-\n                      d\n                      ]pyrimidine inhibitors of ATR kinase. WO 2018218197; 2018."},{"key":"cit0023","unstructured":"Univ Texas. Heterocyclic inhibitors of ATR kinase. WO 2019036641; 2019."},{"key":"cit0024","author":"Univ Texas","year":"2019","journal-title":"WO 2019014618"},{"key":"cit0025","author":"Univ Texas","year":"2019","journal-title":"WO 2019178590"},{"key":"cit0026","unstructured":"Lab A. 1,7-Naphthyridine derivatives as P38 map kinase inhibitors. WO2008017461; 2008."},{"key":"cit0027","unstructured":"Bayer Pharma AG. 2-(morpholin-4-yl)-l, 7-naphthyridines. WO 2016020320; 2016."},{"key":"cit0028","unstructured":"Atrin Pharma LLC. Ataxia telangiectasia and rad3-related (ATR) protein kinase inhibitors. WO 2016061097; 2016."},{"key":"cit0029","unstructured":"Atrin Pharma LLC. Ataxia telangiectasia and rad3-related (ATR) inhibitors and methods of their use. US 20170291911; 2017."},{"key":"cit0030","unstructured":"Merck Patent Gmbh. Tricyclic heterocylic derivatives. WO 2017202748; 2017."},{"key":"cit0031","unstructured":"Astrazeneca AB. Pyriidine indole derivatives for treating cancer. WO 2010073034; 2010."},{"key":"cit0032","unstructured":"Merck Patent Gmbh. 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives. WO 2020049017; 2020."},{"key":"cit0033","unstructured":"Sichuan Kelun Botai Biomedical CO. LTD. Substituted pyrimidine compound, and preparation method and applications thereof. CN 110467610; 2019."},{"key":"cit0034","unstructured":"Sichuan Kelun Botai Biomedical CO. LTD. Substituted pyrido [3, 4-b] pyrazine-2 (1H)-ketone compound and preparation method and application thereof. CN 111848605; 2020."},{"key":"cit0035","unstructured":"Jiangsu Hengrui Medicine Co., Ltd. Preparation of (morpholinyl)dihydropyrrolo[2,3-d]pyrimidines as ATR kinase inhibitors and used for treatment or prevention of tumors. CN 113135942; 2021."},{"key":"cit0036","unstructured":"Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo-heteroaryl derivative, preparation method and medical use. WO 2021098811; 2021."},{"key":"cit0037","unstructured":"Repare Therapeutics INC. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors. WO 2020087170; 2020."},{"key":"cit0038","unstructured":"Merck Patent Gmbh. 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives. WO 2020049017; 2020"},{"key":"cit0039","unstructured":"Rheinisch Westfaelische Techische Hochschule Aachen RWTH. New ATR inhibitors for the use in cancer therapy. WO 2018029117; 2018."},{"key":"cit0040","unstructured":"Bluevalley Pharma LLC. Substituted pyrrolopyridines as ATR inhibitors. WO 2019050889; 2019."},{"key":"cit0041","unstructured":"Medshine Discovery INC. ATR inhibitor and application thereof. WO 2019154365; 2019."},{"key":"cit0042","unstructured":"Shanghai Yingpai Pharma Co. Ltd. Substituted fused heteroaromatic bicyclic compound used as kinase inhibitor and use thereof. CN 112142744; 2020."},{"key":"cit0043","unstructured":"Merrimack Pharma NC. Inhibiting ataxia telangiectasia and rad3-related protein (ATR). WO 2017123588; 2017."},{"key":"cit0044","unstructured":"Beijing Tide Pharma CO. LTD. 2,4,6-trisubstituted pyrimidine compounds as ATR kinase inhibitors. CN 112047938; 2020."},{"key":"cit0045","unstructured":"Fundacion CT. Chemical entities. WO 2014140644; 2014."},{"key":"cit0046","unstructured":"Shanghai De Novo Pharma CO. LTD. Heterocyclic fused pyrimidine derivative, pharmaceutical composition thereof, and application thereof. WO 2020103897; 2020."},{"key":"cit0047","unstructured":"Betta Pharma CO. LTD. ATR inhibitor and application thereof. CN 112851668; 2021."},{"key":"cit0048","unstructured":"Shijiazhuang Sagacity New Drug Development Co., Ltd. Crystalline form of ATR inhibitor and use thereof. WO 2021023272; 2021."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20102162"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.573"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00426"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6915"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02404"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01406-w"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01405-x"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0305"},{"key":"cit0057","first-page":"e213441","author":"Pal SK","year":"2021","journal-title":"JAMA Oncol"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0019"},{"key":"cit0059","volume-title":"Abstract 983: identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models","author":"Luecking UT","year":"2017"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0868"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-1026"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107518"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1021\/jm301859s"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01187"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2018.06.001"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0251"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1032"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3153"},{"key":"cit0069","unstructured":"U.S. National Library of Medicine database. 2021 Sept 30. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04170153"},{"key":"cit0070","volume-title":"Abstract 1226: highly specific ATR inhibitors as a therapeutic approach for a broad spectrum of cancers","author":"Butler LR","year":"2016"},{"key":"cit0071","volume-title":"Abstract 3498: highly specific macrocyclic ATR inhibitors for the targeted treatment of a broad spectrum of cancers showing lack of anemia or neutropenia in pre-clinical animal models","author":"Pamarthy S","year":"2019"},{"key":"cit0072","unstructured":"U.S. National Library of Medicine database. 2021 Sept 30. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04905914"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e18000"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0010"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-021-00571-y"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3626"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab628"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184601"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.035"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2027911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T18:28:38Z","timestamp":1648146518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2027911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,13]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,3]]}},"alternative-id":["10.1080\/13543776.2022.2027911"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2027911","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}